Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Reduced by Tredje AP fonden

Tredje AP fonden reduced its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.6% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 19,483 shares of the biopharmaceutical company’s stock after selling 308 shares during the quarter. Tredje AP fonden’s holdings in Alnylam Pharmaceuticals were worth $4,734,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ALNY. Capital International Investors lifted its holdings in shares of Alnylam Pharmaceuticals by 15.8% in the fourth quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock valued at $686,641,000 after buying an additional 488,814 shares during the period. Vanguard Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after acquiring an additional 287,064 shares during the last quarter. Capital Research Global Investors boosted its position in shares of Alnylam Pharmaceuticals by 7.3% during the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after purchasing an additional 214,908 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Alnylam Pharmaceuticals by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after purchasing an additional 201,784 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter worth approximately $18,886,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 32,450 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the sale, the director now directly owns 136 shares of the company’s stock, valued at approximately $30,013.84. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO Yvonne Greenstreet sold 8,301 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $1,917,447.99. Following the transaction, the chief executive officer now directly owns 80,534 shares in the company, valued at $18,602,548.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the sale, the director now owns 136 shares of the company’s stock, valued at approximately $30,013.84. The disclosure for this sale can be found here. Insiders have sold a total of 103,148 shares of company stock worth $25,658,824 over the last 90 days. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.5 %

Shares of NASDAQ:ALNY opened at $273.15 on Thursday. The stock has a market capitalization of $34.55 billion, a PE ratio of -102.41 and a beta of 0.38. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $287.55. The firm has a fifty day moving average price of $259.23 and a 200 day moving average price of $196.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. During the same quarter last year, the company posted ($2.21) EPS. The business’s revenue was up 107.0% compared to the same quarter last year. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ALNY. HC Wainwright restated a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, August 30th. UBS Group raised their price objective on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a “buy” rating in a research note on Friday, June 28th. Bank of America increased their price target on Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. JPMorgan Chase & Co. boosted their price objective on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. Finally, Leerink Partners upped their price target on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a research report on Tuesday, June 25th. Seven equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $279.14.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.